INT6479

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 5.10
Pain Relevance 2.78

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (IL1B) signal transduction (IL1B) extracellular space (IL1B)
aging (IL1B) extracellular region (IL1B) cell-cell signaling (IL1B)
IL1B (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 14 100.00 Very High Very High Very High
cytokine 67 99.08 Very High Very High Very High
anakinra 27 98.46 Very High Very High Very High
Inflammation 111 97.28 Very High Very High Very High
rheumatoid arthritis 112 96.84 Very High Very High Very High
spinal inflammation 5 96.24 Very High Very High Very High
Arthritis 21 87.52 High High
headache 8 81.68 Quite High
Bioavailability 2 81.52 Quite High
Osteoarthritis 385 79.48 Quite High
Disease Link Frequency Relevance Heat
INFLAMMATION 132 97.28 Very High Very High Very High
Cerebral Malaria 51 97.28 Very High Very High Very High
Rheumatoid Arthritis 114 96.84 Very High Very High Very High
Low Back Pain 5 96.24 Very High Very High Very High
Necrosis 14 88.48 High High
Cancer 14 88.12 High High
Arthritis 36 87.52 High High
Repression 3 85.60 High High
Syndrome 68 85.40 High High
Sepsis 4 82.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In addition, the concentration of IL-1 receptor antagonist (IL-1RA), which competes for receptor binding with IL-1, was also found to be increased in Gambian children with cerebral malaria [4].
Negative_regulation (competes) of IL-1 Binding (binding) of associated with antagonist and cerebral malaria
1) Confidence 0.43 Published 2005 Journal Malar J Section Body Doc Link PMC1224865 Disease Relevance 0.70 Pain Relevance 0.13
IL-1 receptor antagonist (IL-1Ra) is a protein that binds to IL-1 receptors and competitively inhibits the binding of IL-1alpha and IL-1beta.
Negative_regulation (inhibits) of IL-1beta Binding (binding) of associated with antagonist
2) Confidence 0.42 Published 2005 Journal J. Rheumatol. Section Abstract Doc Link 16206345 Disease Relevance 0.59 Pain Relevance 0.48
The IL-1 receptor antagonist blocks IL-1 binding to cells but has no IL-1 activity of itself.
Negative_regulation (blocks) of IL-1 Binding (binding) of associated with antagonist
3) Confidence 0.37 Published 1992 Journal Kidney Int. Suppl. Section Abstract Doc Link 1328757 Disease Relevance 0.85 Pain Relevance 0.40
B translocation SN-50, blocked the suppressive effect of IL-1, suggesting the involvement of NF-?
Negative_regulation (suppressive) of IL-1 Binding (effect) of
4) Confidence 0.24 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906809 Disease Relevance 0 Pain Relevance 0
As shown in Figure 6b, treatment with IL-1 decreased PPAR?
Negative_regulation (decreased) of IL-1 Binding (treatment) of
5) Confidence 0.24 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906809 Disease Relevance 0.15 Pain Relevance 0.03
B translocation SN-50, blocked the suppressive effect of IL-1, suggesting the involvement of NF-?
Negative_regulation (blocked) of IL-1 Binding (effect) of
6) Confidence 0.24 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906809 Disease Relevance 0 Pain Relevance 0
Current therapy targeting IL-1 in RA is based on a recombinant form of the IL-1 receptor antagonist (IL-1Ra; anakinra), which binds to the IL-1 receptor without eliciting a signal and therefore competes with the binding of the two natural ligands, namely IL-1?
Negative_regulation (competes) of IL-1 Binding (binding) of associated with anakinra, antagonist and rheumatoid arthritis
7) Confidence 0.12 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2483458 Disease Relevance 1.18 Pain Relevance 0.61
and neutralizes its activity by blocking its interaction with IL-1 receptors with peak serum concentration occurring approximately 7 days after subcutaneous administration of a single, 150 mg dose.
Negative_regulation (blocking) of IL-1 Binding (interaction) of
8) Confidence 0.11 Published 2010 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2880341 Disease Relevance 0.62 Pain Relevance 0.15
These include receptor blockade, neutralization of the cytokine by soluble receptors or monoclonal antibody, blocking the formation of active IL-1?
Negative_regulation (blocking) of IL-1 Binding (formation) of associated with cytokine
9) Confidence 0.09 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526599 Disease Relevance 0.65 Pain Relevance 0.57
The latter protein blocks the binding of IL-1?
Negative_regulation (blocks) of IL-1 Binding (binding) of
10) Confidence 0.07 Published 2008 Journal Current Genomics Section Body Doc Link PMC2691664 Disease Relevance 0.35 Pain Relevance 0.41

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox